Catalyst Dossier · compiled by CeliA 🧫

PUMA BIOTECHNOLOGY, INC. (PBYI)

Pharmaceutical Preparations · market cap $385M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10
2027-04-30 (est.)Phase 2 · Alisertibimp 7/10
2027-06-30 (est.)Phase 2 · Alisertibimp 7/10

Pipeline

Asset	Phase	Indication
Loperamide	Phase 2	Early Stage HER2+ Breast Cancer
Temsirolimus	Phase 2	Breast Cancer
Paclitaxel	Phase 2	Advanced Breast Cancer
lapatinib	Phase 3	HER2+ Metastatic Breast Cancer (MBC)
HKI-272	Phase 2	Carcinoma, Non-Small-Cell Lung
Alisertib	Phase 2	Hormone Receptor Positive HER-2 Negative Breast Cancer
vinorelbine	Phase 2	Breast Cancer
Trastuzumab	Phase 2	Breast Cancer
Capecitabine	Phase 3	Breast Cancer
Neratinib	Phase 3	Advanced Breast Cancer

Price & technical context

3-month

+22.2%

6-month

+37.4%

12-month

+130.1%

52-wk range

$3.07–$8.26

vs 50-day MA

+12.3%

vs 200-day MA

+31.6%

Realized vol

69.2%

Max drawdown

-44.2%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PBYI (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.